X0609 4 2026-07-21 1 0001964979 ALLURION TECHNOLOGIES, INC. ALUR 0001493215 RTW INVESTMENTS, LP false 40 10TH AVENUE, 7TH FLOOR NEW YORK NY 10014 false false true false 0001493280 WONG RODERICK false 40 10TH AVENUE, 7TH FLOOR NEW YORK NY 10014 0 0 1 0 0 Common Stock, $0.0001 par value per share 2026-07-21 4 J 0 209254 D 0 I See footnotes Common Stock, $0.0001 par value per share 2026-07-21 4 J 0 161807 D 0 I See footnotes Common Stock, $0.0001 par value per share 2026-07-21 4 J 0 19934 D 0 I See footnotes Common Stock, $0.0001 par value per share 2026-07-21 4 J 0 1771 D 0 I See footnotes Pre-Funded Warrant (Right to Buy) 0.0001 2026-07-21 4 J 0 209254 A Common Stock 209254 209254 I See Footnotes Pre-Funded Warrant (Right to Buy) 0.0001 2026-07-21 4 J 0 161807 A Common Stock 161807 161807 I See footnotes Pre-Funded Warrant (Right to Buy) 0.0001 2026-07-21 4 J 0 19934 A Common Stock 19934 19934 I See footnotes Pre-Funded Warrant (Right to Buy) 0.0001 2026-07-21 4 J 0 1771 A Common Stock 1771 1771 I See footnotes On July 21, 2026, RTW Master Fund, Ltd. ("Master Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a "Pre-Funded Warrant"). RTW Investments, LP (the "Adviser") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. ("RTW Innovation"), RTW Biotech Opportunities Operating Ltd. ("RTW Biotech Fund") and other funds or accounts managed by the Adviser (each, an "Other RTW Fund"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Held directly by Master Fund. On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 161,807 shares of the Issuer's Common Stock. Held directly by RTW Innovation. On July 21, 2026, RTW Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of the Issuer's Common Stock. Held directly by RTW Biotech Fund. On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock. Held by an Other RTW Fund. The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. On June 18, 2026, the Issuer effected a 1-for-15 reverse stock split. The share counts herein reflect the reverse stock split. /s/ Roderick Wong, M.D. - For RTW Investments, L.P., By: Roderick Wong, M.D., Managing Partner 2026-07-23 /s/ Roderick Wong, M.D. 2026-07-23